Introduction
The last decade has seen that several of the dominant and recessive forms of hypo-and hyperphosphatemic bone disease have received their molecular explanation. This has led to new insight into the pathophysiology of hypo-and hyperphosphatemic bone disease, as well as the understanding of a bone-kidney axis which operates integrated and in parallel with the classical parathyroid-kidney axis in the regulation of phosphorus content in the body. In addition, it has led to the recognition of a Janus face of some of the involved genes, showing both hyper-and hypofunction, dependent on the nature of the mutation. In this book chapter, we will present an update on the emerging insight of monogenic hypo-and hyperphosphatemic disorders.
Genetic mechanisms and pathophysiology
Hypophosphatemia may lead to bone or dental disease resulting from decreased mineralization (calcification) of bone or dental matrix or osteoid. The simultaneous blood calcium levels will also influence the degree of mineralization. Hypophosphatemia leads to rickets in children or to osteomalacia in adults. In many of the hypophosphatemic conditions, there is also an impairment of renal activation of vitamin D, further aggravating disease. The mineralization of teeth can also be affected, and there are clinical forms where bone affection is minimal and the dental disorders dominate. Hyperphosphatemia may lead to increased mineralization of both bone and non-bone tissues (ectopic calcification) due to an increase in the body content of phosphorus. This results in tumoral calcinosis with calcification of muscles, skin and vessels. The monogenic forms affect the renal handling of phosphorus by various mechanisms resulting from inactivation or activation of the involved genes. With the advancement of genetic insight and the subsequent possibility to study subjects with mutations and a wide range of phenotypes, a broader phenotypic pattern is recognized. Consequently, we suggest the more appropriate terms of monogenic hypophosphatemia and monogenic hyperphosphatemia for these disorders, and that the specific disorders should be classified according to the affected gene, e.g. PHEXhypophosphatemia and FGF23-hyperphosphatemia (Table 1 ). We will now provide an overview of the genes directly implicated in monogenic phosphate balance disorders. Please refer to textbooks for a discussion of genes indirectly affecting phosphate balance (i.e. genes leading to defective parathyroid gland development or disrupted PTH receptor function).
DMP1
AR hypophosphatemic rickets DMP1-hypophosphatemia
GALNT3
Familial hyperphosphatemic tumoral calcinosis
GALNT3-hyperphosphatemia

FGF23
AD hypophosphatemic rickets FGF23-hypophosphatemia Familial hyperphosphatemic tumoral calcinosis
FGF23-hyperphosphatemia
FGFR1
Osteogophonic dysplasia with hypophosphatemia FGFR1-hypophosphatemia
KL
Hypophosphatemic rickets and hyperparathyroidism
KL-hypophosphatemia
Hyperphosphatemic tumoral calcinosis KL-hyperphosphatemia
SLC34A1
Hypophosphatemic nefrolithiasis/ osteoporosis
SLC34A1-hypophosphatemia
SLC34A3
HHRH
SLC34A1-hypophosphatemia
SLC9A3R1
Hypophosphatemic nephrolithiasis/ osteoporosis
SLC9A3R1-hypophosphatemia
ENPP1
AR hypophosphatemic rickets, type 2 ENPP1-hypophosphatemia 
PHEX
The PHEX (Phosphate-regulating endopeptidase homolog, XB; MIM* 300550) gene consists of 22 exons (Sabbagh, Boileau et al. 2003) and was positionally cloned in 1995 (HYP Consortium 1995 (Jonsson, Zahradnik et al. 2003; Juppner 2007; Bastepe and Juppner 2008) .
(See section 2.11 for a discussion on the physiological and pathophysiological mechanisms involved.) The protein is also believed to be involved in bone and dentin mineralization. Both the whole-body and bone-specific (osteocalcinpromoted inactivation) knockout mouse model of PHEX as well as the spontaneous Hyp mouse model display increased bone production, increased levels of serum FGF23, decreased kidney membrane NPT2 and osteomalacia (Yuan, Takaiwa et al. 2008) . Cell studies indicate mechanistic defects both during protein processing in the endoplasmic reticulum and cell membrane (Sabbagh, Boileau et al. 2001 ) and as abrogated catalytic activity (Sabbagh, Boileau et al. 2003) . There are several mutations associated with PHEX-hypophosphatemia (see the PHEX mutation database: http://www.phexdb.mcgill.ca/) and most of the mutations are located in the region encoding the extracellular domain, but there are also examples of pathological mutations in the 5'UTR (Dixon, Christie et al. 1998 ) and 3'UTR (Ichikawa, Traxler et al. 2008) of the gene. Fig. 1 . PHEX gene structure and the corresponding encoded regions. Adapted from (Sabbagh, Boileau et al. 2003) .
There is no clear genotype-phenotype correlation (Holm, Nelson et al. 2001 ). There is a slight dominance of familiar mutations (showing co-segregation with disease in a pedigree) to de novo mutations (sporadic) reported in literature (Holm, Nelson et al. 2001 ). The penetrance is high, although there are examples of non-penetrance (Gaucher, WalrantDebray et al. 2009 ). The expressivity varies (Brame, White et al. 2004 ).
DMP1
The DMP1 gene (dentin matrix acidic phosphoprotein 1; MIM* 600980) gene consists of 6 exons on chromosome 4q21, and was first implicated in a phosphate balance disorder in 2006 Lorenz-Depiereux, Bastepe et al. 2006) . DMP1 is highly expressed in osteocytes, and is a member of the 'SIBLING' (small integrin binding ligand n-linked glycoprotein) family of non-collagenous extracellular matrix proteins involved in bone mineralization (Huq, Cross et al. 2005) . The DMP1 knockout model displays rickets and osteomalacia with isolated renal phosphate wasting associated with elevated FGF23 levels and normocalciuria (Feng, Ward et al. 2006) . In humans, homozygous or compound heterozygous mutations in DMP1 leads to hypophosphatemic rickets with elevated FGF23, isolated phosphate wasting, and no evidence of hypercalciuria. The exact relation between DMP1 and FGF23 levels is not known, but in vitro studies have shown that vitamin D increases the expression of both (Farrow, Davis et al. 2009 ). There are only a few reported mutations in the literature (Feng, Ward et al. 2006 ; LorenzDepiereux, Bastepe et al. 2006; Farrow, Davis et al. 2009; Koshida, Yamaguchi et al. 2010; Makitie, Pereira et al. 2010; Turan, Aydin et al. 2010) , making DMP1 mutations a rare cause of hypophosphatemic rickets ). 
GALNT3
The O-glycosylation of serine and threonine residues on many glycoproteins depend on enzymatic catalyzation of the reaction UDP-GalNAc + polypeptide-(Ser/Thr)-OH to GalNAc-alpha-O-Ser/Thr-polypeptide + UDP. GalNAcT3 is one of 24 members in the UDPGalNAc:polypeptide N-acetylgalactosaminyltransferase protein family involved in this process. GalNAcT3 is encoded by the GALNT3 gene (MIM *601756) on chromosome 2q24-q31, which contains 10 exons. GalNAcT3 is thought to protect FGF23 from proteolysis (Kato, Jeanneau et al. 2006) by O-glycosylation, and a deactivating mutation in GALNT3 will thus lead to increased breakdown of FGF23. Mutations in GALNT3 were the first to be associated with familial tumoral calcinosis (FTC) (Topaz, Shurman et al. 2004) , and are also seen in the closely related disease, the hyperphosphatemic hyperostosis syndrome (HHS). These are the only diseases known to be caused by mutations in the family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Although the process of O-glycosylation is important in many tissues, mutations in GALNT3 lead to a very restricted phenotype with hyperphosphatemia, periarticular calcifications and hyperostosis. This is thought to be explained by functional redundancy of this protein family. In addition to the effects on bone and renal phosphate handling caused by altered FGF23 metabolism, mutations in GALNT3 are also thought to have direct effect in the process of ectopic calcification in extraosseous tissues (Chefetz and Sprecher 2009). www.intechopen.com
FGF23
The FGF23 gene (MIM*605380) on chromosome 12 is composed of 3 exons, and encodes a member of the fibroblast growth factor family. The protein product, FGF23, acts via its receptor FGFR1 (fibroblast growth factor receptor 1, see 2.5), but is also dependent on the co-receptor Klotho (-Klotho) to exert its functions (see below). Furthermore, FGF23 belongs to the FGF19 family where the two other family members, FGF19 and FGF21, (also binding to FGFR1) are dependent on ß -Klotho to exert their functions, illustrating the role of a coreceptor to ensure tissue specificity and function (Kurosu, Choi et al. 2007 ). FGF23 exerts its physiological effects on the kidney by the downregulation of the CYP27B1 gene leading to a loss of compensatory increase in 1,25(OH) 2 vitamin D levels, and by the endocytosis of the type IIa and IIc Na/phosphate (Pi) cotransporters (Npt2a and Npt2c) from the renal proximal tubular brush border membrane. Heterozygous activating mutations in the cleavage site RXXR motif of exon 3 of FGF23, leads to stabilization and decreased degradation of the FGF23. The clinical phenotype is autosomal dominant hypophosphatemic rickets 2000) . Homozygous inactivating missense mutations in FGF23 lead to hyperphosphatemic familial tumoral calcinosis, due to decreased renal excretion of phosphate and increased renal α-hydroxylation of vitamin D (Benet-Pages, Orlik et al. 2005; Ichikawa, Baujat et al. 2010 ).
FGFR1
The Fibroblast growth factor receptor 1 gene FGFR1 (MIM*136315) located on chromosome 8p11 encodes a protein member of the FGFR (1-4) family, where the members are all receptor tyrosine kinases. FGFR1-3 are implicated in skeletal development, and various mutations in the corresponding genes are responsible for a number of skeletal dysplastic syndromes (Passos-Bueno, Wilcox et al. 1999 ). There are several subclasses of FGFRs, depending on the number of immunoglobulin-like loops and splicing differences in the third loop. FGFR1C combines with Klotho (KL) to become the functional receptor for FGF23 (Urakawa, Yamazaki et al. 2006) . Mutations in the FGFR1C lead to constitutive activation of the receptor and subsequent downregulation of the expression of the sodium-phosphate co-transporters NaPiIIa and NaPiIIc, as well as the downregulation of the CYP27B1 gene leading to a loss of compensatory increase in 1,25(OH)2vitamin D levels (Shimada, Hasegawa et al. 2004 ).
KL
Klotho (KL) (MIM*604824) is located to chromosome 13q12, comprises 5 exons, and encodes the protein Klotho (also known as α-Klotho), which in mice is considered a hormone with anti-aging properties (Kurosu, Yamamoto et al. 2005) . KL knockout mice will go through a rapid aging process, and have decreased insulin secretion and increased insulin sensitivity (Kuro-o, Matsumura et al. 1997) , while overexpression of KL leads to a prolonged life span in mice (Kurosu, Yamamoto et al. 2005 ). In addition, Klotho has been associated with disturbances of phosphate metabolism, as it is an obligate co-receptor for the binding of FGF23 to FGFR1C. In humans, there are two KL transcripts; one encoding a membrane bound protein and one encoding a secreted protein. Human KL is expressed mainly in the kidney, and the secreted variant seems to dominate (Matsumura, Aizawa et al. 1998 ). Recent findings from mouse studies suggest that Klotho has endocrine, paracrine and autocrine effects independent of FGF23 (Hu, Shi et al. 2010) .
Inactivating mutations will lead to familial hyperphosphatemic tumoral calcinosis, similar to the phenotypes seen in GALNT3-hyperphosphatemia and FGF23-hyperphosphatemia ). There is also one report of an activating translocation of the KL gene, leading to hypophosphatemic rickets with a phenotype similar to PHEX-hypophosphatemia but with additional distinctive dysmorphic features of the head (Brownstein, Adler et al. 2008 ).
SLC34A1
The solute carrier 34 (SLC34) gene family includes the three genes SLC34A1, SLC34A2 and SLC34A3, all encoding sodium/phosphate cotransporters. SLC34A2 encodes the intestinal NaPi-IIb, and will not be further discussed. SLC34A1 and SLC34A3 encode the two renal sodium/phosphate cotransporters, and the latter is described in 2.8 section. The SLC34A1 (MIM*182309) gene is expressed in the renal proximal tubule, and encodes the type IIa Na/Pi cotransporter (NaPi-IIa), which plays a central role in renal phosphate handling in various animal models. The expression of NaPi-IIa in the brush border membrane is regulated at the post translational level, by endocytosis and lysosomal degradation or microtubular recruitment (Tenenhouse 2005) . Both PTH and FGF23 lead to increased endocytosis of NAPi-IIa, and thus decreased reabsorption of Pi from filtered urine, whereas hypophosphatemia and 1,25 dihydroxyvitamin D stimulate phosphate reabsorption (Tenenhouse 2005) . There also seems to be a directly regulating effect of dietary Pi on Na/Pi cotransport in proximal tubules, and the existence of an intestinal-renal axis for phosphate regulation has been proposed [review: (Biber, Hernando et al. 2009)] . NaPi-IIa double knockout mice have hypophosphatemia, phosphaturia, elevated 1,25 dihydroxyvitamin D with resulting hypercalcemia, hypercalcuria and nephrocalcinosis/nephrolithiasis (Beck, Karaplis et al. 1998 ). This phenotype resembles hereditary hypophosphatemic rickets with hypercalcuria (HHRH) seen in humans, which interestingly is not caused by mutations in SLCA34A1, but rather by mutations in SLC34A3 (NaPi-IIc) (see 2.8). In man, a few cases have been described of heterozygous mutations in SLC34A1, leading to a syndrome of hypophosphatemia, osteoporosis and nephrolithiasis (Prie, Huart et al. 2002) .
SLC34A3
The human SLC34A3 (MIM*609826) gene, consists of 13 exons on chromosome 9q34, and h o m o z y g o u s m u t a t i o n s i n t h i s g e n e l e a d t o hereditary hypophosphatemic rickets with hypercalciuria (HHRH) (Bergwitz, Roslin et al. 2006; Lorenz-Depiereux, Benet-Pages et al. 2006) . The phenotype of HHRH resembles that of NaPi-IIa knockout mice, but the patients also display rickets or osteomalacia. In animal models the type IIc Na/Pi cotransporter (NaPi-IIc) has been shown to play a more minor role in proximal tubular phosphate resorption than NaPi-IIa. The opposite might be the case in man (Amatschek, Haller et al. 2010 ).
SLC9A3R1
The SLC9A3R1 (MIM*604990) gene on chromosome 17 encodes the protein NHERF1 (sodium/hydrogen exchanger regulatory factor 1), which plays a part in maintaining the cytoskeleton in polarized cells with microvilli, such as renal tubular cells. Three different mutations in SLC9A3R1 have recently been identified in 7 subjects with hypophosphatemia due to phosphaturia, nephrolithiasis and osteoporosis (Karim, Gerard et al. 2008 ).
ENPP1
The ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) (MIM*173335) gene on chromosome 6q22-q23 comprises 23 exones and encodes a type II transmembrane glycoprotein ectoenzyme responsible for the generation of inorganic pyrophosphate (PPi). PPi is an inhibitor of hydroxyapatite crystal growth, and also suppress chondrogenesis. In mice, ENPP1 is expressed in plasma cells, on hepatocytes, renal tubules, salivary duct epithelium, epididymis, capillary endothelium in the brain, and chondrocytes (Harahap and Goding 1988) . In man it has been shown that ENPP1 is expressed in liver, cartilage and bone, and is thought to regulate physiological mineralization processes and pathological chondrocalcinosis (Huang, Rosenbach et al. 1994) . Homozygous mutations in ENPP1 are known to cause generalized arterial calcifications of infancy (GACI) (Rutsch, Vaingankar et al. 2001; Rutsch, Ruf et al. 2003) . Recently, homozygous mutations in ENPP1 have been shown to cause autosomal recessive hypophosphataemic rickets (Levy-Litan, Hershkovitz et al. 2010) . In some families, identical mutations cause GACI in some family members and hypophosphatemic rickets in other family members (Lorenz-Depiereux, Schnabel et al. 2010) . Prolonged survival in GACI has been observed in subjects who have simultaneously displayed renal phosphate loss (Rutsch, Boyer et al. 2008) . Mutations in ENPP1 have also been associated with susceptibility to insulin resistance and obesity (Goldfine, Maddux et al. 2008 ). Figure 3 shows the integrated physiological and pathophysiological mechanisms in the renal phosphate regulation. The parathyroid-renal axis has been the traditional model explaining how PTH stimulates the renal tubular cells to phosphaturia as a negative feedback loop response to elevated phosphate levels ( Figure 3A ). In this model PTH acts via its receptor to block the sodium-phosphate co-transporters NaPiIIa and NaPiIIc encoded by the SLC34A1 and SLC34A3 genes, respectively. In addition, PTH stimulates the CYP27B1 gene leading to a compensatory increase in 1,25(OH) 2 vitamin D levels as a negative feedback loop to reduced serum levels of 1,25(OH) 2 vitamin D and calcium. There is, however, also a PTH-independent pathway where hormonal substances from bone, phosphatonins, stimulate the renal tubular cells to phosphaturia in a negative feedback response to elevated serum phosphate and 1,25(OH) 2 vitamin D levels. Recent emerging insight has laid the foundation for this model of a bone-kidney axis (Quarles 2003) , where fibroblast growth factor 23 (FGF23) seems to be the central phosphatonin inhibiting phosphate reabsorption and hence inducing phosphaturia ( Figure 3B ). In contrast to PTH, FGF23 inhibits CYP27B1 gene leading to an absent compensatory increase in 1,25(OH) 2 vitamin D levels, recognized by clinicians as inappropriate normal 1,25(OH) 2 vitamin D levels. In the normal state PHEX and DMP1 gene products seem to inhibit FGF23 production, whereas the GALNT3 gene product seems to stimulate FGF23 production. By interfering with the bone-kidney axis, increased FGF23 levels seem to play a central role in the pathogenesis of PHEX-hypophosphatemia (Jonsson, Zahradnik et al. 2003) ( Figure 3C ) and potentially also DMP1-hypophosphatemia (Lorenz-Depiereux, Bastepe et al. 2006; Turan, Aydin et al. 2010 ) and FGF23-hypophosphatemia (Imel, Hui et al. 2007 ), but the mechanisms are still poorly known (Strom and Juppner 2008) . It is also poorly known how increased FGF23 levels in FGF23-hyperphosphatemia and GALNT3-hyperphosphatemia explain the opposite condition of hyperphosphatemia (Topaz, Shurman et al. 2004; Benet-Pages, Orlik et al. 2005) . A current model postulates that mutations in PHEX lead to increased FGF23 production by cancelled PHEX-mediated inhibition of FGF23 production (Figure 3 C) . Both the parathyroid-renal axis and the bone-kidney axis seem to be negative feedback loops where increased serum phosphate levels compared to a biological set value leads to phosphaturia. These two axes are different with respect to 1,25(OH) 2 vitamin D: Whereas low 1,25(OH) 2 vitamin D levels stimulating 1,25(OH) 2 vitamin D activation is the major regulation in the parathyroid-renal axis, high 1,25(OH) 2 vitamin D levels inhibiting 1,25(OH) 2 vitamin D activation is the major regulation in the bone-kidney axis. Recent work also points to interactions between these feedback loops where FGF23 inhibits PTH, whereas PTH possibly stimulates FGF23 ( Figure 3D ). Mutations in genes encoding the sodium-phosphate co-transporters such as SLC34A1, SLC34A3 and SLC9A3R1 lead to increased phosphaturia but since the 1,25(OH) 2 vitamin D activation is unaffected, there is a normal compensatory increase in 1,25(OH) 2 vitamin D levels. Whether gene mutations lead to hypophosphatemia or hyperphosphatemia is dependent on the location of the gene product in the pathways outlined above and whether the mutation is activating or inactivating the affected gene.
An integrated model for the physiological and pathophysiological mechanisms in the renal phosphate regulation
Diagnostic considerations
The diagnosis of monogenic hypo-or hyperphosphatemia requires the demonstration of affected phosphate balance in patients in which acquired causes of phosphate disturbance have been excluded. A family history of rickets, kidney stones, soft tissue calcification, bone deformities or recurrent fractures, as well as an indication of monogenic inheritance pattern is usually found, unless the patient seems to represent a sporadic case. In the case of hypophosphatemia, there is typically low plasma phosphate, low renal tubular reabsorption of phosphate (% TRP) and tubular threshold maximum for phosphate for glomerular filtration rate (TmP/GFR), raised alkaline phosphatase, normal PTH, and inappropriate and normal 25(OH) and 1,25(OH) 2 vitamin D levels. Moreover, the urinary calcium excretion is normal, whereas X-ray changes may demonstrate rickets or osteomalacia. FGF23 levels are typically high, either due to overproduction or under-catabolism, and in children with rickets, the combined evaluation of FGF23 and PTH leads differential diagnosis in the direction of impaired phosphate homeostasis (high FGF23 and normal PTH) or altered metabolism of vitamin D, calcium or magnesium (low FGF23 and high PTH) (Alon 2010 ). In the case of hyperphosphatemia, there is usually high plasma phosphate, an inappropriate normal % TRP and TmP/GFR, a low or normal PTH and normal renal function. In some cases, the clinical picture and inheritance pattern will suggest a specific genetic diagnosis, and, in addition, the blood FGF23 levels and hypercalciuria may differentiate between different genetic disorders of phosphate balance, although the clinical role of blood FGF23 levels is at present not fully elucidated.
PHEX
PHEX-hypophosphatemia (X-linked dominant) is usually a progressive disorder with a typical onset at the age when the child starts to walk. The most common clinical manifestations include genu varus, radiological rickets, short stature, bone pain, dental abscesses and calcification of tendons, ligaments and joint capsules with boys being more severely affected than girls and a wide variation between families (Econs, Samsa et al. 1994; Carpenter 1997; Bastepe and Juppner 2008) . Some patients may even have craniosynosteosis and spinal stenosis. Many patients suffer from long lasting dental problems, particularly tooth decay and recurrent spontaneous dental abscesses that occur in the absence of a history of trauma or dental decay. Histological findings include high pulp horns, globular dentin, and defects of dentin and enamel. The primary teeth are most commonly affected, as the mineralization process starts in utero. Permanent teeth develop after birth, and adequate treatment improve development in some cases (Batra, Tejani et al. 2006) . In children with rickets, a low serum phosphorus level, combined with high serum alkaline phosphatase and normal serum calcium is typical (Carpenter 1997) . Urinary leakage of phosphate is demonstrated by low % TRP and TmP/GFR, whereas urinary calcium is normal. The PTH levels are usually normal or slightly elevated, even before the onset of therapy. The 25(OH)vitamin D is normal, and there is no compensatory increase in 1,25(OH) 2 vitamin D levels due to defective renal activation of vitamin D, and, hence, no hypercalciuria. The FGF23 levels are increased (Jonsson, Zahradnik et al. 2003) , and since the lower extremities are more severely affected than the other parts of the skeleton, radiographs of the knees and ankles will demonstrate the extent of rickets. The diagnosis of PHEX-hypophosphatemia is confirmed by genetic analysis.
DMP1
DMP1-hypophosphatemia (autosomal recessive) is usually a progressive disorder with a typical onset at the age when the child starts to walk. The condition is rarer than PHEXhypophosphatemia, but is phenotypically quite similar to PHEX-and FGF23-hypophosphatemie. There is no compensatory increase in 1,25(OH) 2 vitamin D levels due to defective renal activation of vitamin D and hence no hypercalciuria. The circulation levels of FGF23 are increased (Feng, Ward et al. 2006) . The degree of skeletal abnormalities varies between families (Makitie, Pereira et al. 2010) . Some patients also have dental affection, with hypomineralization, enlarged pulp chambers, and decrease in the dentin and enamel layers, which can cause dental abscesses and loss of teeth (Koshida, Yamaguchi et al. 2010; Turan, Aydin et al. 2010 ).
GALNT3
GALNT3-hyperphosphatemia is the result of biallelic mutation in the GALNT3-gene, and leads to typical tumoral calcinosis (TC) (Topaz, Shurman et al. 2004) or hyperostosishyperphosphatemia syndrome (HHS). There are several mutations in the GALNT3 gene, and the same mutation can lead to TC in some patients and HHS in other (Ichikawa, Baujat et al. 2010) . TC is characterized by ectopic calcifications in soft tissues and around large joints, recognized clinically as palpable masses and/or on radiography. Calcifications may also be found in the retina, in blood vessels, as testicular microlithiasis, and there might be dental abnormalities. HHC is characterized by hyperostosis of long bones, seen radiographically as cortical hyperostosis, diaphysitis and periosteal apposition. The biochemical findings in TC and HHC are similar, with elevated serum phosphate levels, increased or normal 1,25(OH)2vitamin D levels. The levels of serum calcium and parathyroid hormone are normal. Some authors suggest that TC and HHS are clinical variants of the same disease (Ichikawa, Baujat et al. 2010) .
FGF23
FGF23-hypophosphatemia (autosomal dominant) shows a variable age at onset of disease. The expression of disease varies, and some children may have fracture tendency without skeletal deformities, whereas other children may have only temporary renal phosphate loss . Tooth abscesses and loss also occurs (Imel, Hui et al. 2007 ). FGF23-hyperphosphatemia (autosomal recessive) shows typical tumoral calcinosis , or more rarely the hyperostosis-hyperphosphatemia syndrome (Benet-Pages, Orlik et al. 2005) .
FGFR1
FGFR1R-hypophosphatemia is characterized by osteoglophonic dysplasia and can be associated with hypophosphatemia (Farrow, Davis et al. 2006) . Clinical features are skeletal abnormalities leading to dwarfism and facial abnormalities similar to achondroplasia. There is often failure of tooth eruption, and mandibular malformations. Patients may also have various degrees of craniosynostosis (White, Cabral et al. 2005 ).
KL
To date only one case of KL-hypophosphatemia has been described in the literature (Brownstein, Adler et al. 2008) . A 1-year old girl suffered from poor linear growth and increasing head size. She had clinical and radiological signs of rickets, hypophosphatemia, renal phosphate wasting and elevated levels of parathyroid hormone and alkaline phosphatase. A balanced translocation between chromosomes 9 and 13 was detected (t(9,13)(q21.13;q13.1)). This translocation had led to upregulation of KLtranscription. After a few years she demonstrated dysmorphic features of the face, and also an Arnold-Chiari 1 malformation (Brownstein, Adler et al. 2008) . Dental affection has not been described. KL-hyperphosphatemia has also been described in only one report . A 13 year old girl presented with severe calcifications in soft tissues and in the vasculature, including the dura and the carotid arteries. In addition to hyperphosphatemia and hypercalcemia, she presented with hyperparathyroidism and elevated levels of FGF23. She had no signs of premature aging, which is seen in KL knockout mice. Dental affection has not been described.
SLC34A1 and SLC34A3
In SLC34A1-and SLC34A3-hypophosphatemia, there is hypophosphatemic rickets with hypercalciuria without other tubular defects (Tieder, Modai et al. 1985) . The inheritance pattern is autosomal recessive. Since there is normal renal activation of vitamin D (in contrast to PHEX-hypophosphatemia and DMP1-hypophosphatemia), hypophosphatemia leads to a normal compensatory increase in 1,25(OH) 2 vitamin D levels and increased absorption of calcium and phosphate from the gut.
SLC9A3R1
A total of 7 cases of SLC9A3R1-hypophosphatemia (hypophosphatemia, nephrolithiasis/osteoporosis) have been described to date (Karim, Gerard et al. 2008) . All patients were adults, and had either nephrolithiasis and/or bone demineralization combined with hypophosphatemia and hyperphosphaturia. 1,25 (OH)2 vitamin D levels were either elevated or in the upper normal range. Dental affection has not been described.
ENPP1
ENPP1-hypophosphatemia (autosomal recessive) has a variable age at onset and a variable phenotype including Generalized Arterial Calcification of Infancy (GACI). Also there seems to be phenotypic variation within the same family among affected subjects carrying the same mutation. Whereas the classic presentation is that of severe arterial calcification leading to death in infancy, some patients have renal phosphate wasting and hypophosphatemia. This phosphate loss seems to attenuate the tendency of arterial calcifications, and is associated with prolonged survival (Lorenz-Depiereux, Schnabel et al. 2010 
Management principles
Hypophosphatemia
Hypophosphatemic rickets is in childhood usually treated with elementary phosphorus at doses preferentially between 30 and 60 (100) mg/kg bodyweight and 24 hours, usually divided by 4-6 doses, whereas the deficient 1,25(OH) 2 vitamin D production is treated with active vitamin D, e.g. alphacalcidol or calcitriol in doses of 20 to 70 ng/kg bodyweight and 24 hours, usually divided by 2 doses. It should, however, be emphasized that the dosage ranges for both phosphate and active vitamin D are wide, dependent on the severity of the disease, the compliance and the occurrence of complications. In SLC34A1-and SLC34A3-hypophosphatemia, activation of vitamin D is normal, and, consequently, there is no need for treatment with vitamin D. It is important to adjust the drug doses individually and bear in mind that insufficient doses of elementary phosphorus and vitamin D may fail to prevent or correct skeletal deformities (rickets, osteomalacia) and can lead to growth retardation. On the other hand, excessive doses may lead to nephrocalcinosis (high phosphate doses), as well as hypercalciuria and hypercalcemia (high vitamin D levels). Secondary (and even tertiary) hyperparathyroidism is seen in patients with insufficient doses of vitamin D or excessive doses of phosphorus. We recommend aiming at normal levels of PTH, which in severe cases may be obtained by adding the calcimimetic drug cinacalcet to the treatment (Raeder, Bjerknes et al. 2008 ). Close monitoring is necessary to balance the effects of phosphorus supplement and active vitamin D. Growth, serum calcium, phosphorus, alkaline phosphatase, PTH, as well as urinary calcium/creatinine ratio should be determined every 3-6 months, and X-rays of ankles, knees and wrist should be taken yearly. Renal ultrasound should be obtained yearly to assess nephrocalcinosis. Supplementary treatment with growth hormone is currently not recommended for the growth retardation caused by hypophosphatemia (Huiming and Chaomin 2005) , but may be warranted in selected cases. Corrective osteotomies are seldom necessary in childhood, and it should always be deferred until the rickets has healed. Future therapeutic possibilities may include direct targeting of blood FGF23 levels.
Hyperphosphatemia
Patients with hyperphosphatemia due to monogenic phosphate balance disorders, i.e. GALNT3-hyperphosphatemia, FGF23-hyperphosphatemia and KL-hyperphosphatemia, develop ectopic and vascular calcifications. Combined use of intestinal phosphate binders and the carbonic anhydrase inhibitor acetazolamide has been reported to lower serum phosphorus levels and reduce tumoral masses in some patients (Garringer, Fisher et al. 2006) . However, other reports suggest that neither medical nor surgical treatment seems to be effective in controlling ectopic calcifications in these conditions (Carmichael, Bynum et al. 2009 ). Future therapeutic possibilities may include direct targeting of blood FGF23 levels.
Genetic diagnostics and predictive testing
Identification of a specific mutation has important therapeutic and prognostic implications and tailored follow-up as outlined above. Distinction between PHEX-hypophosphatemia and DMP1-hypophosphatemia can be done clinically based on the inheritance pattern, but in some cases there is an ambiguous inheritance pattern (Figure 4 ) and a genetic test will resolve this ambiguity.
www.intechopen.com Monogenic phosphate balance disorders warrant genetic counseling, because of the known inheritance pattern and the high penetrance. This is also the case for novel gene variants where it is necessary to establish evidence for causality based on co-segregation studies and prediction tools (such as Polyphen http://genetics.bwh.harvard.edu/pph/)). Predictive genetic testing is less straightforward, and the legal regulations vary in different countries. Communicating genetic information can be difficult and it is important to take into account how well the individual understands both genetics in general and the disorder itself and the consequences of potentially diagnosing other family subjects. The basic fact that there is a 25% or 50% probability for a child to carry the family's mutation should be conveyed to the parents. In addition, the probability for the development of the disorder in the presence of a mutation (i.e. the penetrance) is not always 100%. The variable and in some cases unpredictable age of onset of some of the disorders should also be discussed. By increasing knowledge of the clinical spectrum of mutations, novel expected manifestations need to be discussed with the patient. A system for follow-up is required for children without a phenotype but with affected family members and where parents still request that their child be tested. This follow-up may include periodic testing for hypophosphatemia, with a frequency dependent on age and the suspected condition.
Research perspectives
We have established a national database of patients with hypophospahtemic bone disorder in order to study phenotype-genotype correlation in this disease and to be able to explore novel pathophysiologic pathways based on insight obtained from studies of families with no previously known genetic cause of monogenic hypophosphatemic bone disorder. We believe that a new classification of disease based on genetic etiology instead of clinical criteria may facilitate the finding of new phenotypes since it will facilitate the study of unobserved phenotypes, both in the patients and in their presumably unaffected relatives carrying mutations. In addition, it is possible that emerging new treatment options may vary based on the genetic diagnosis which warrants studies of associations between gene variants and therapeutic effects. Future studies of monogenic phosphate balance disorders will probably continue to include genomewide studies of families with genetically unexplained phosphate balance disorders. Animal and cell studies will probably also continue to contribute to the understanding of disease mechanism, and, in particular, the use of induced pluripotent stem cells (iPS) seems to be a promising new tool in the mechanistic and therapeutic studies (Rosenzweig 2010) as well as the use of small molecule screens in the search for new therapeutic options in monogenic disease (Shaw, Blodgett et al. 2011) .
Conclusion
As we have discussed in this book chapter, several of the dominant and recessive forms of hypo-and hyperphosphatemic bone disease have received their molecular explanation leading to new insight into the pathophysiology of hypo-and hyperphosphatemic bone disease. The major advancement in pathophysiological understanding has come from the understanding of a bone-kidney axis where the central bone phosphatonin FGF23 acts on FGFR1-receptors in the kidneys to promote phosphaturia and from the understanding of all the factors converging on this axis. In fact, this axis ties together the known monogenic forms of renal phosphate disorders. In addition, the understanding of the genetics and pathophysiology of these disorders has led to the recognition of the two faces of some of the involved genes, showing both hyper-and hypofunction, dependent on the nature of the mutation, which is in particular the case for mutations affecting the KL and FGF23 genes. We recommend the use of a genetic-oriented classification instead of the traditional diseaseoriented classification since we believe that this will facilitate a broader understanding of the phenotype of monogenic phosphate balance disorders. Whereas increased molecular understanding has led to a more precise diagnosis, it has not yet led to new established treatment. We believe, however, that the molecular understanding will indeed facilitate the development of new treatment options with the use of the powerful tools including iPS cells and small molecular screens.
